Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The rapidly evolving stem cell space may have matured to the level where a single company’s misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following Osiris Therapeutics’ recent announcement that its mesenchymal stem cell therapy Prochymal produced mixed results in an interim look at a study of 62 patients with chronic obstructive pulmonary disease.

You may also be interested in...

Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies

"The idea of giving up and going home is simply not in the cards," CEO Mills says.

Osiris/Genzyme Anticipates Approval Of Stem Cell Therapy Prochymal By 2010

Osiris begins the FDA submission process for its mesenchymal stem cell therapy Prochymal this quarter, making a late-2009 approval of the world's first stem cell therapy a possibility if the agency grants a six-month review, and a first-cycle approval

Geron Gets Green Light To Test Embryonic Stem Cell Therapy On Humans

After being delayed since May, Geron’s 21,000-page application clears overnight in the first week of the Obama administration.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts